EUCTR2021-005192-39-NL进行中（未招募）1 期
Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to be eligible to participate in this study, subject must meet the following:
- •1.Histologically confirmed LBCL and associated subtypes, defined by WHO 2016 classification
- •2.Tumor lesion(s) of which a histological biopsy can safely be obtained according to standard clinical care procedures.
- •3.Measurable disease, as defined by Lugano criteria
- •4.If has history of CNS disease, then must have no signs or symptoms of CNS disease, no active disease on magnetic resonance imaging (MRI) and absence of large cell lymphoma in cerebral spinal fluid (CSF) on cytospin preparation and flow cytometry, regardless of the number of white blood cells.
- •5. If has history of cerebral vascular accident (CVA)
- •a.The CVA event must be >12 months prior to apheresis
- •b.Any neurological deficits must be stable
- •6.Signed informed consent.
- •7.Age =18 at the time of signing informed consent.
- •8.Life expectancy =12 weeks.
- •9.Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •10.Ability to comply with the protocol.
- •11.For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception (i.e., one that results in a low failure rate [< 1% per year] when used consistently and correctly).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Signs or symptoms of active infection within 2 weeks prior to 89Zr-atezolizumab injection, unless treated to resolution.
- •2.Prior CD19-directed CAR T-cell therapy or other bi-specific antibodies targeting CD19 receptor (e.g. blinatumomab).
- •3.History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
- •4.Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of 89Zr-atezolizumab, or that may affect the interpretation of the results or render the patient at high risk from complications.
- •5.Pregnant or lactating women.
- •6.HIV-positive patients
研究者
相似试验
招募中
2 期
Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study.lymphomaNL-OMON56151niversitair Medisch Centrum Groningen20
进行中（未招募）
2 期
PD-L1 PET-imaging During CAR T-cell TherapyLarge B-cell LymphomaNCT05404048University Medical Center Groningen20
撤回
1 期
An imaging study of 64Cu-SARTATE using positron emission tomography in paediatric patients with high-risk neuroblastoma.ACTRN12617001259336Clarity Pharmaceuticals LTD10
招募中
不适用
Positron emission computed tomography (PET) with L-[11C] methioninemalignant tumorJPRN-UMIN000010237Yamaguchi University School of Medicine300
招募中
不适用
PD-L1 Targeting Molecular Imaging of Solid TumorsGastrointestinal TumorsNCT04629326Peking University Cancer Hospital & Institute20